Molecure reports lower half-year loss as Molecure stock was last at PLN 7.10

Published on 10/05/2026 at 18:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Molecure stock was last at PLN 7.10 on October 5, 2026, while first-half revenue fell to PLN 1.86447 million. Net loss narrowed to PLN 6.30707 million.

Molecure, PLONCTH00011, Illustration mit AI erstellt.

Molecure stock (ISIN PLONCTH00011) was last at PLN 7.10 on the WSE on October 5, 2026, at 4:59 p.m. CEST. The biotechnology company reported a lower first-half net loss of PLN 6.30707 million for 2026, compared with PLN 8.52034 million in the same period of 2025, according to BiznesRadar on September 30, 2026.

Loss narrows in first half

Operating revenue fell to PLN 1.86447 million in the first half of 2026 from PLN 3.52343 million a year earlier. Operating costs excluding the incentive program declined to PLN 8.20471 million from PLN 12.65398 million, giving the report a clear cost-control angle.

Net operating cash flow was negative PLN 1.38736 million in the first half of 2026, compared with negative PLN 10.64403 million in the first half of 2025. The figures show a smaller loss alongside lower revenue, leaving clinical progress more important to the company valuation than current sales.

Cash supports clinical programs

Cash and cash equivalents stood at PLN 24.912771 million on June 30, 2026, compared with PLN 16.35 million at December 31, 2025, BIZNES24 reported on October 1, 2026.

Molecure said its KITE study for OATD-01 had more than 40 randomized patients and a goal of reaching 50 in the coming months, according to BIZNES24. The company is also developing OATD-02 in Phase I and an artificial intelligence platform for drug discovery.

October report sets next checkpoint

Molecure's investor calendar lists publication of its third-quarter 2026 report for October 30, 2026, while the company describes OATD-01 as its most advanced proprietary drug candidate on its investor page. That date gives the market a defined checkpoint for cash use, patient recruitment and clinical milestones.

Stock stays below yearly high

Molecure stock was last at PLN 7.10 on October 5, 2026, with a session range of PLN 6.71 to PLN 7.56. The 52-week range was PLN 4.98 to PLN 9.04, while market capitalization stood at PLN 175.5 million and volume reached 41,955 shares.